Kidney Mass Found in a 63-Year-Old Man

Poll

A 63-year-old man presents with a mass in the left kidney. After further evaluation, a biopsy is performed. What is your diagnosis?

A 63-year-old man presents with a mass in the left kidney. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Oncocytoma
B. Renal cell carcinoma, chromophobe type
C. Angiomyolipoma
D. Metastatic adenocarcinoma
Recent Videos
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Related Content
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC

Belzutifan Improves PFS Across Subgroups for Advanced ccRCC

Ashling Wahner
July 12th 2024
Article

“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Manageable AEs Noted in Belzutifan for Advanced RCC

Manageable AEs Noted in Belzutifan for Advanced RCC

Gina Mauro
July 12th 2024
Article

“This is currently the largest pooled safety dataset for a HIF-2α inhibitor we need to be familiar with,” lead study author Toni K. Choueiri, MD.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Collecting and analyzing patient data through an AI tool may help with more accurately predicting outcomes and personalizing treatment.

Multimodal AI Approach May Predict Outcomes in Renal Cell Carcinoma

Ariana Pelosci
July 11th 2024
Article

Collecting and analyzing patient data through an AI tool may help with more accurately predicting outcomes and personalizing treatment.

Data from CheckMate 214 show a steady improvement in overall survival with nivolumab/ipilimumab in patients with favorable-risk disease.

Nivolumab Combo May Show Long-Term Benefits in Advanced RCC

Russ Conroy
July 11th 2024
Article

Data from CheckMate 214 show a steady improvement in overall survival with nivolumab/ipilimumab in patients with favorable-risk disease.